TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2024

Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis.

Ferda Cevikbas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.